Clinical trials: Influenza (Healthy Volunteers)
Influenza, Human
A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers
This is a study to assess the immune (antibody) response and safety of the 2013/2014 formulation of Enzira® vaccine in healthy adult volunteers aged 18 years or older.
- Trial name
- NCT01857297
- Testing
- Enzira® vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Immunogenicity and Safety Evaluation of QIS in Healthy Subjects
The purpose of this study was to evaluate the antibody response to each of the four influenza vaccine strains included in the study vaccine, as measured by hemagglutination inhibition (HAI) at 4 weeks after the last dose of the…
- Trial name
- NCT04101435
- Testing
- AdimFlu-S (QIS)
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza, Vaccine
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost with or without adjuvant.
- Trial name
- NCT03300050
- Testing
- cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza
Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults
The purpose of this study is to examine the safety and tolerability after administration of trivalent and quadrivalent cell-based virosomal influenza vaccine in healthy adults.
- Trial name
- NCT02148328
- Testing
- Trivalent virosomal influenza vaccine, Commercial vaccine 1, Quadrivalent virosomal influenza vaccine
- Where
- 4 sites in Belgium
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Avian Influenza
A Safety and Immunogenicity Study of IVACFLU-A/H5N1
The study hypothesis was that two 0.5 mL doses of whole virion monovalent A/H5N1 influenza vaccine (IVACFLU-A/H5N1) adjuvanted with alum would be safe and well tolerated in healthy adults, and that at least one of the two doses…
- Trial name
- NCT02612909
- Testing
- IVACFLU-A/H5N1 vaccine
- Where
- 2 sites in Vietnam
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Influenza
Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects
The purpose of this study is to evaluate the safety and pharmacokinetic profile of flufirvitide-3 nasal spray in healthy subjects.
- Trial name
- NCT01313962
- Testing
- Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
Seasonal Influenza
A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
The study of quadrivalent influenza vaccine manufactured by Sinovac Biotech Co., Ltd will conduct in two phases,the phaseⅠclinical trial of the study will be open-label design,and the phase III clinical trial of the study will be…
- Trial name
- NCT05245552
- Testing
- Quadrivalent influenza vaccine(0.25ml), Quadrivalent influenza vaccine(0.5ml), Trivalent influenza vaccine(BV)
- Where
- 4 sites in China
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Human Volunteers
A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1
This is a first in human, phase I, open label study of the MVA viral vector (produced in the novel immortalised duck retinal cell line AGE1.CR.pIX) expressing the influenza antigens NP and M1 as a fusion protein, in healthy adult…
- Trial name
- NCT03277456
- Testing
- MVA-NP+M1
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Influenza, Human
Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses
A single center trial to evaluate the effect of POLB 001 on inflammatory responses following an intradermal LPS challenge in healthy volunteers.
- Trial name
- NCT05765955
- Testing
- POLB 001
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Poolbeg Pharma plc
Healthy Volunteers
Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection
This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.
- Trial name
- NCT05447078
- Testing
- Immulina TM
- Where
- United States
- Volunteers
- 492 people, healthy volunteers welcome
- Sponsor
- University of Mississippi Medical Center
Influenza
A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing.
- Trial name
- NCT00375206
- Testing
- Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)
- Where
- 2 sites in United States
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- PowderMed
Influenza
Intracutaneous Delivery of Varied Dose Volumes of Saline
This study will evaluate intracutaneous delivery of 0.1, 0.25 and 0.5 milliliter volumes of saline from the FLUGEN 101.2 investigational microneedle-based device.
- Trial name
- NCT01767337
- Testing
- FLUGEN 101.2 device
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza, Flu
A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects
Despite currently available antivirals, influenza causes significant morbidity and mortality, with 226,000 excess hospitalizations and 30,000-50,000 deaths each year in the United States alone, and more therapies are needed in…
- Trial name
- NCT02037282
- Testing
- Anti-influenza IVIG
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteer
Intranasal AD4-H5-VTN as an Adenovirus Vaccine
Background: Adenoviruses are viruses that typically cause symptoms of a cold or eye infection. These viruses are being tested as part of a possible new vaccine.
- Trial name
- NCT01806909
- Testing
- Ad4-H5-Vtn
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958
This study will look at the safety, tolerability and what the body does to CS-8958 given to 40 healthy volunteers 18-55 years old.
- Trial name
- NCT00311714
- Testing
- CS-8958 formulated as dry powder
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Influenza
Pilot Influenza Challenge Study
This is a research study to understand what happens when a person is infected with influenza ("flu") and how the body controls the infection.
- Trial name
- NCT07063849
- Testing
- A/Texas
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Daniel Hoft, MD, PhD
Influenza A, Pandemic Influenza
H7HLAII DNA Influenza Vaccine
The purpose of this study is to assess safety and immunogenicity of H7HLAII, a DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class…
- Trial name
- H7N9vax-1 (NCT06046092)
- Testing
- H7HLAII
- Where
- Norway
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Influenza, Human
A Study to Determine the Safety and Attack Rate of the Seasonal Flu in Healthy Volunteers
This is a non-controlled, open-label, single-centre, dose-escalation study to determine the safety, infectivity and immunology of the potential novel influenza virus H3N2 challenge strain.
- Trial name
- NCT04372719
- Testing
- H3N2
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SGS Life Sciences, a division of SGS Belgium NV
Respiratory Syncytial Virus (RSV)
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
Up to 220 eligible subjects will be enrolled into one of five treatment groups. It is anticipated that some of the randomized study subjects may not complete the study; subjects who withdraw or are discontinued, will not be…
- Trial name
- NCT01709019
- Testing
- Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
- Where
- 4 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza, Human
VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...
Objectives: To evaluate the safety and tolerability of a prime-boost study regimen that includes the recombinant DNA vaccine followed by licensed 2008/2009 FluLaval(Registered Trademark) in adults ages 18-50 years and adults ages…
- Trial name
- NCT00858611
- Testing
- VRC-FLUDNA047-00-VP, Flulaval (Registered) Seasonal Influenza Vaccine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)